Table 2.

Plasma levels of MMP-7, TIMP-1, HE4 and CA 125 in tested groups (statistically significant when p < 0.05)

Groups		MMP-7 (ng/ml)	TIMP-1 (ng/ml)	HE4 (pmol/L)	CA125 (U/ml)
Ovarian cancer Median Range	Stage I	a, b4.76 1.98–17.86	a108.35 4.60–328.90	a, b118.70 34.50–1093.80	a66.73 10.60–557.20
	Stage II	a, b4.73 2.24–18.00	151.70 15.20–839.00	a, b120.90 38.30–1205.70	a, b61.45 9.80–2060.78
	Stage III	a, b, d7.92 1.98–17.80	a, b, d241.20 26.00–554.70	a, b, d650.55 48.70–1810.60	a, b, d766.20 10.10–2742.00
	Stage IV	a, b, d12.27 2.00–27.40	a, b, d252.60 28.00–642.00	a, b372.95 37.80–1944.20	a, b, d541.13 14.30–8602.30
	Total group	a, b5.60 1.98–27.40	a, b170.79 4.60–839.00	a, b207.09 34.50–1944.20	a, b139.70 9.80–8602.30
Control groups Median Range	Benign ovarian tumor total group	3.18 1.33–24.25	107.00 6.71–309.06	57.70 34.90–202.90	c22.90 5.80–748.00
	Healthy subjects	3.25 1.75–8.42	128.88 23.38–266.09	54.00 15.00–408.89	12.70 1.49–36.60

^aStatistically significant when comparing EOC patients with healthy subjects

^bStatistically significant when comparing EOC patients with benign ovarian tumor total group

^cStatistically significant when comparing patients with benign ovarian tumor and healthy subjects

^dStatistically significant when comparing EOC patients in stage III or IV with stage I or II